

Todos Medical Ltd.

10:15 20 Oct 2020

Todos Medical receives notice of allowance from the European Patent Office covering the use of its TBIA platform to detect benign colon cancer in peripheral blood

Todos Medical Ltd. (OTCQB:TOMDF) announced that it has received a notice of allowance from the European Patent Office covering the use of the company's Total Biochemical Infrared Analysis (TBIA) platform to detect benign colon cancer in peripheral blood.

The TBIA platform uses spectroscopy-based infrared analysis method to analyze immune cells in the blood or order to turn the biological information in the blood into data, and then mines that data using artificial intelligence to develop algorithms that are predictive of cancer and other diseases that impact the immune system, including bacteria and viruses. TBIA's lead programs are in the detection of breast cancer and colon cancer.

READ: Todos Medical says it has contracts that may deliver over \$60M in revenue by end of 2Q 2021

"We are very pleased that we've received this notice of allowance for TBIA in benign tumors as it further adds to our market-leading position as an AI-based cancer blood screening company," said Gerald E. Commissiong, President & CEO of Todos Medical in a statement.

"In particular, the method underlying this IP could be quite complementary to existing screening methods by adding additional information to help physicians distinguish between benign (polyps) and malignant tumors of the colon using a simple blood test. Taken in combination with some of our other patents and patent applications that cover the detection of malignant tumors of the colon, we believe we now have intellectual property that fully supports commercialization of our TBIA cancer platform for colon cancer."

The global market for in-vitro colorectal cancer (CRC) testing is estimated to reach \$1.2 Billion by 2025, growing at a CAGR of 8.7% over the forecast period, driven by higher incidence and prevalence for colon and rectum cancers, colorectal polyps screening and improved treatment over the last few decades. Aging population and rising incidences of colorectal cancer, diabetes, inflammatory bowel disease, inherited syndrome, obesity, and smoking are some of the factors driving the in vitro CRC testing market.


According to the American Cancer Society (2018), an estimated 135,430 people were diagnosed with colorectal cancer in the United States. The American Cancer Society's estimates number of 95,520 new cases of colon cancer and 39,910 new cases of rectal cancer in the United States for 2017.

Headquartered in Rehovot, Israel, Todos Medical is an in vitro diagnostics company focused on distributing comprehensive solutions for coronavirus (COVID-19) screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer's disease.

Price: 0.0679

Market Cap: \$13.71 m

1 Year Share Price Graph



Share Information

Code: TOMDF

Listing: OTCQB

52 week High Low
0.1815 0.0111

Sector: Medical technology & services

Website: todosmedical.com

Company Synopsis:

Todos Medical Ltd. (OTCQB: TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic ("IVD") company developing a series of blood tests for the early detection of a variety of cancers. Our new cancer tests will add a layer to currently available cancer screening and diagnostics. Our goal is to help save lives through early detection while being minimally invasive to the patient.

action@proactiveinvestors.com

Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire US.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Contact the author at jon.hopkins@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).